Почетна › Рак на бели дробови со не-мали клетки › Охајо › Cincinnati
Клинички испитувања за Рак на бели дробови со не-мали клетки во Cincinnati, OH
35 студии за Рак на бели дробови со не-мали клетки бараат учесници на локации во и околу Cincinnati (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Се регрутираФаза 3
- University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103), Cincinnati
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Се регрутираФаза 3
- University of Cincinnati Medical Center ( Site 0119), Cincinnati
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Се регрутираФаза 3
- The Christ Hospital, Cincinnati
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Се регрутираФаза 3
- Local Institution - 0383, Cincinnati
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Се регрутираФаза 3
- University of Cincinnati Cancer Center, Cincinnati
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Се регрутираФаза 3
- TriHealth Cancer & Blood Institute Research, Cincinnati
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Се регрутираФаза 3
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- и уште 1
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Се регрутираФаза 3
- Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0061), Edgewood · на 8 милји
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Се регрутираФаза 3
- Oncology Hematology Care Clinical Trials, Cincinnati
- Oncology Hematology Care Clinical Trials, Cincinnati
- Oncology Hematology Care Clinical Trials, Cincinnati
- и уште 1
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Се регрутираФаза 2
- Cincinnati Veterans Affairs Medical Center, Cincinnati
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Се регрутираФаза 3
- Research Site, Cincinnati
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Се регрутираФаза 3
- University of Cincinnati Medical Center, Cincinnati
- Saint Elizabeth Medical Center Edgewood, Edgewood · на 8 милји
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Се регрутираФаза 3
- Saint Elizabeth Medical Center Edgewood, Edgewood · на 8 милји
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Се регрутираФаза 2/3
- The Christ Hospital Cancer Center, Cincinnati
- University of Cincinnati Medical Center, Cincinnati
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Се регрутираФаза 3
- Research Site, Cincinnati
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Се регрутираФаза 3
- Clinical Study Sites, Cincinnati
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Се регрутираФаза 2/3
- Local Institution - 007-893-B, Cincinnati
- USOR - Oncology Hematology Care - Blue Ash, Cincinnati
- Local Institution - 007-893-C, Cincinnati
- и уште 1
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Се регрутираФаза 2/3
- Oncology Hematology Care, Inc - Blue Ash /ID# 262733, Cincinnati
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Се регрутираФаза 1/2
- Christ Hospital, Cincinnati
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Се регрутираФаза 3
- USO - Oncology Hematology Care, Cincinnati
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Се регрутираФаза 1
- University of Cincinnati (UC) - Cancer Institute, Cincinnati
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Се регрутираФаза 1
- St. Elizabeth Healthcare, Edgewood · на 8 милји
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Се регрутираФаза 3
- University of Cincinnati Medical Center, Cincinnati
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Се регрутираФаза 2
- University of Cincinnati Medical Center, Cincinnati
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Се регрутираФаза 1/2
- University of Cincinnati, Cincinnati
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Се регрутираФаза 1
- The Christ Hospital, Cincinnati
MYLUNG Consortium Part 3: Observational Study
Се регрутираНабљудувачка студија
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Се регрутираФаза 1/2
- Christ Hospital Cancer Center, Cincinnati
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Се регрутираФаза 2
- St. Elizabeth Healthcare, Edgewood · на 8 милји
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Се регрутираФаза 1/2
- Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center, Cincinnati
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
Се регрутира
- University of Cincinnati Medical Center, Cincinnati
GEMINI-NSCLC: NSCLC Biomarker Study
Се регрутираНабљудувачка студија
- TriHealth Cancer Institute, Cincinnati
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Се регрутираФаза 1/2
- Research Site 113, Cincinnati
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Се регрутираНабљудувачка студија
- Massive Bio SYNERGY-AI site, Cincinnati
A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.
Се регрутираФаза 2
- The Christ Hospital, Cincinnati
Испитувања за Рак на бели дробови со не-мали клетки во други градови
- Houston, TX145 студии
- New York City, NY121 студија
- Arlington, VA104 студии
- Nashville, TN97 студии
- Boston, MA90 студии
- Los Angeles, CA87 студии
- St. Louis, MO73 студии
- Chicago, IL61 студија
- Baltimore, MD60 студии
- San Antonio, TX59 студии
- Columbus, OH57 студии
- Washington, DC55 студии
Други студии во Cincinnati
- Рак (сите типови)27 студии
- Рак на дојка25 студии
- Срцева слабост24 студии
- Колоректален карцином21 студија
- Метастатски карцином21 студија
- Акутна миелоидна леукемија20 студии
- Карцином на јајниците19 студии
- Дебелина19 студии
- Рак на бели дробови19 студии
- Рак на простата18 студии
- Меланом17 студии
- Множен миелом17 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.